Literature DB >> 10811118

Functional assay for BRCA1: mutagenesis of the COOH-terminal region reveals critical residues for transcription activation.

F Hayes1, C Cayanan, D Barillà, A N Monteiro.   

Abstract

The breast and ovarian cancer susceptibility gene product BRCA1 is a tumor suppressor, but its precise biochemical function remains unknown. The BRCA1 COOH terminus acts as a transcription activation domain, and germ-line cancer- predisposing mutations in this region abolish transcription activation, whereas benign polymorphisms do not. These results raise the possibility that loss of transcription activation by BRCA1 is crucial for oncogenesis. Therefore, identification of residues involved in transcription activation by BRCA1 will help understand why particular germ-line missense mutations are deleterious and may provide more reliable presymptomatic risk assessment. The BRCA1 COOH terminus (amino acids 1560-1863) consists of two BRCTs preceded by a region likely to be nonglobular. We combined site-directed and random mutagenesis, followed by a functional transcription assay in yeast: (a) error-prone PCR-induced random mutagenesis generated eight unique missense mutations causing loss of function, six of which targeted hydrophobic residues conserved in canine, mouse, rat, and human BRCA1; (b) random insertion of a variable pentapeptide cassette generated 21 insertion mutants. All pentapeptide insertions NH2-terminal to the BRCTs retained wild-type activity, whereas insertions in the BRCTs were, with few exceptions, deleterious; and (c) site-directed mutagenesis was used to characterize five known germ-line mutations and to perform deletion analysis of the COOH terminus. Deletion analysis revealed that the integrity of the most COOH-terminal hydrophobic cluster (I1855, L1854, and Y1853) is necessary for activity. We conclude that the integrity of the BRCT domains is crucial for transcription activation and that hydrophobic residues may be important for BRCT function. Therefore, the yeast-based assay for transcription activation can be used successfully to provide tools for structure-function analysis of BRCA1 and may form the basis of a BRCA1 functional assay.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10811118      PMCID: PMC4893312     

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  Structure of an XRCC1 BRCT domain: a new protein-protein interaction module.

Authors:  X Zhang; S Moréra; P A Bates; P C Whitehead; A I Coffer; K Hainbucher; R A Nash; M J Sternberg; T Lindahl; P S Freemont
Journal:  EMBO J       Date:  1998-11-02       Impact factor: 11.598

2.  Common BRCA1 variants and transcriptional activation.

Authors:  A N Monteiro; A August; H Hanafusa
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

3.  BRCA1 is a component of the RNA polymerase II holoenzyme.

Authors:  R Scully; S F Anderson; D M Chao; W Wei; L Ye; R A Young; D M Livingston; J D Parvin
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

4.  Induction of phosphorylation on BRCA1 during the cell cycle and after DNA damage.

Authors:  J E Thomas; M Smith; J L Tonkinson; B Rubinfeld; P Polakis
Journal:  Cell Growth Differ       Date:  1997-07

5.  Correlation of two-hybrid affinity data with in vitro measurements.

Authors:  J Estojak; R Brent; E A Golemis
Journal:  Mol Cell Biol       Date:  1995-10       Impact factor: 4.272

6.  Elimination of false positives that arise in using the two-hybrid system.

Authors:  P Bartel; C T Chien; R Sternglanz; S Fields
Journal:  Biotechniques       Date:  1993-06       Impact factor: 1.993

7.  Yeast-based assays for detection and characterization of mutations in BRCA1.

Authors:  A N Monteiro; J S Humphrey
Journal:  Breast Dis       Date:  1998-04

8.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.

Authors:  D F Easton; D T Bishop; D Ford; G P Crockford
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

Review 9.  Inherited breast and ovarian cancer.

Authors:  C I Szabo; M C King
Journal:  Hum Mol Genet       Date:  1995       Impact factor: 6.150

10.  Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells.

Authors:  J Chen; D P Silver; D Walpita; S B Cantor; A F Gazdar; G Tomlinson; F J Couch; B L Weber; T Ashley; D M Livingston; R Scully
Journal:  Mol Cell       Date:  1998-09       Impact factor: 17.970

View more
  33 in total

1.  Identification of XcpZ domains required for assembly of the secreton of Pseudomonas aeruginosa.

Authors:  Viviane Robert; Finbarr Hayes; Andrée Lazdunski; Gérard P F Michel
Journal:  J Bacteriol       Date:  2002-03       Impact factor: 3.490

2.  BRCA1 variants in a family study of African-American and Latina women.

Authors:  Roberta McKean-Cowdin; Heather Spencer Feigelson; Lucy Y Xia; Celeste Leigh Pearce; Duncan C Thomas; Daniel O Stram; Brian E Henderson
Journal:  Hum Genet       Date:  2005-02-23       Impact factor: 4.132

Review 3.  Functional assays for BRCA1 and BRCA2.

Authors:  Marcelo A Carvalho; Fergus J Couch; Alvaro N A Monteiro
Journal:  Int J Biochem Cell Biol       Date:  2006-08-18       Impact factor: 5.085

4.  TopBP1 contains a transcriptional activation domain suppressed by two adjacent BRCT domains.

Authors:  Roni H G Wright; Edward S Dornan; Mary M Donaldson; Iain M Morgan
Journal:  Biochem J       Date:  2006-12-15       Impact factor: 3.857

5.  Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis.

Authors:  Marcelo A Carvalho; Sylvia M Marsillac; Rachel Karchin; Siranoush Manoukian; Scott Grist; Ramona F Swaby; Turan P Urmenyi; Edson Rondinelli; Rosane Silva; Luis Gayol; Lisa Baumbach; Rebecca Sutphen; Jennifer L Pickard-Brzosowicz; Katherine L Nathanson; Andrej Sali; David Goldgar; Fergus J Couch; Paolo Radice; Alvaro N A Monteiro
Journal:  Cancer Res       Date:  2007-02-15       Impact factor: 12.701

6.  Assessment of functional effects of unclassified genetic variants.

Authors:  Fergus J Couch; Lene Juel Rasmussen; Robert Hofstra; Alvaro N A Monteiro; Marc S Greenblatt; Niels de Wind
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

7.  Understanding missense mutations in the BRCA1 gene: an evolutionary approach.

Authors:  Melissa A Fleming; John D Potter; Christina J Ramirez; Gary K Ostrander; Elaine A Ostrander
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-16       Impact factor: 11.205

8.  Expression of human BRCA1 variants in mouse ES cells allows functional analysis of BRCA1 mutations.

Authors:  Suhwan Chang; Kajal Biswas; Betty K Martin; Stacey Stauffer; Shyam K Sharan
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

9.  Analysis of a set of missense, frameshift, and in-frame deletion variants of BRCA1.

Authors:  Marcelo Carvalho; Maria A Pino; Rachel Karchin; Jennifer Beddor; Martha Godinho-Netto; Rafael D Mesquita; Renato S Rodarte; Danielle C Vaz; Viviane A Monteiro; Siranoush Manoukian; Mara Colombo; Carla B Ripamonti; Richard Rosenquist; Graeme Suthers; Ake Borg; Paolo Radice; Scott A Grist; Alvaro N A Monteiro; Blase Billack
Journal:  Mutat Res       Date:  2008-10-17       Impact factor: 2.433

10.  Evidence for a pathogenic role of BRCA1 L1705P and W1837X germ-line mutations.

Authors:  Anna P Sokolenko; Nikita M Volkov; Elena V Preobrazhenskaya; Evgeny N Suspitsin; Aigul R Garifullina; Alexandr V Ivantsov; Alexandr V Togo; Evgeny N Imyanitov
Journal:  Mol Biol Rep       Date:  2016-03-07       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.